Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04241393 · ClinicalTrials.gov registry record · Phase 1
An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04241393 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT04241393, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of \[14C\] tavapadon.
Interventions
- DRUG Tavapadon tablet
- DRUG Tavapadon [14C] suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-02-04 |
| Est. Completion | 2020-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04241393
The ClinicalTrials.gov registry entry for NCT04241393 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tavapadon tablet is the first listed.
NCT04241393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04241393 about?
NCT04241393 is a clinical study titled "An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects". The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of \[14C\] tavapadon.
What is the current status of trial NCT04241393?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-02-04. Estimated completion is 2020-11-08.
What interventions are being tested in trial NCT04241393?
The interventions under investigation include: Tavapadon tablet (DRUG), Tavapadon [14C] suspension (DRUG).
Who is sponsoring clinical trial NCT04241393?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.